CONTACT@EOLO-PHARMA.COM

Small molecule drugs

for big impact diseases

Discover how at Eolo Pharma we use cutting-edge medical science to create therapeutic solutions to improve the quality of life of our patients.

About us

Eolo Pharma is a clinical-stage biotechnology company pioneering new approaches to treat obesity and metabolic disease. By targeting the body’s energy expenditure pathways, we aim to develop transformative therapies that go beyond traditional weight-loss mechanisms. Our lead candidate, SANA, is the first compound shown to safely activate creatine-dependent thermogenesis in humans, a novel biological process with the potential to reset metabolic health. Backed by over a decade of research, our work reflects a commitment to advancing science-driven solutions that improve lives worldwide.

Founder team

Scientific spinoff institut pasteur de Montevideo​.

María Pia Garat

María Pia Garat

CEO
Dynamic and accomplished young CEO with a strong background in the biotech industry. With a postgraduate education from IE Business School, she brings a unique blend of specialized knowledge and business expertise to her leadership role. Maria Pia’s successful track record of closing investment rounds for Eolo Pharma highlights her strategic aptitude and ability to secure funding. Her combination of biotech industry experience and advanced business education positions her as a perceptive leader, driving the company’s growth and success. Maria Pia Garat’s postgraduate education from IE Business School adds further depth to her leadership capabilities in the biotech industry.
Carlos Escande

Carlos Escande

CSO
Distinguished leader in the field of pharmaceutical research. With a background as an investigator at Mayo Clinic, he brings a wealth of expertise in biomedical science and drug development. Carlos’s innovative approach and commitment to scientific excellence drive the advancement of therapeutic solutions for cardiometabolic disorders. As CSO of Eolo Pharma, he spearheads the company’s research and development efforts, leveraging his extensive knowledge to make a profound impact on patients’ lives.
Virginia Lopez

Virginia Lopez

CCO
Highly accomplished chemist hailing from Uruguay. With her exceptional knowledge and expertise in the field, she has made significant contributions to scientific research and innovation. Virginia’s dedication to her craft, coupled with her meticulous approach to experiments and analysis, has earned her recognition within the scientific community. Her passion for advancing knowledge and solving complex problems through chemistry is evident in her work.
Carlos Batthyany

Carlos Batthyany

CMO
Extensive experience in drug development and medical expertise, Carlos plays a crucial role in driving the company’s clinical development strategies and ensuring the safety and efficacy of their pharmaceutical products. His leadership and deep understanding of the industry contributes to the advancement of innovative therapies and the improvement of patient outcomes. Carlos Batthyany’s dual roles as CMO of Eolo Pharma and Head of the Institut Pasteur de Montevideo make him a highly respected and influential figure in the scientific and pharmaceutical communities.

Board of directors

Nicolas Tognalli

Nicolas Tognalli

BOARD MEMBER
Managing Partner of CITES (Centro de Innovación Tecnológica, Empresarial y Social S.A.), a venture builder owned by Grupo Sancor Seguros. With a strong focus on scientific and technological startups, CITES manages $30 million in early-stage venture capital investments. Nicolas plays a key role in co-creating and transforming these startups into global enterprises. His strategic management expertise and investment acumen drive the growth and success of innovative, science-based companies within the CITES portfolio.
Paul Elberse

Paul Elberse

BOARD MEMBER
Seasoned professional with expertise in large-scale project development in renewable energy and hydrogen sectors. His cross-sectoral experience includes M&A and venture capital investments in biotech and innovation. His strategic insights and extensive network contribute to successful project execution and investment decisions. Paul’s passion for sustainable solutions drives his commitment to advancing renewable energy and biotech industries through impactful projects and investments.
Roland Haag

Roland Haag

BOARD MEMBER
Accomplished professional with over 30 years of experience in the health industry. His expertise spans various sectors, including pharmaceuticals, healthcare management, and medical devices. Roland’s extensive experience provides him with a deep understanding of the industry’s intricacies and a proven track record of driving successful outcomes. His strategic insights and leadership skills have made a significant impact in shaping the health industry and delivering innovative solutions for improved patient care.
Carlos Escande

Carlos Escande

BOARD MEMBER
Distinguished leader in the field of pharmaceutical research. With a background as an investigator at Mayo Clinic, he brings a wealth of expertise in biomedical science and drug development. Carlos’s innovative approach and commitment to scientific excellence drive the advancement of therapeutic solutions for cardiometabolic disorders. As CSO of Eolo Pharma, he spearheads the company’s research and development efforts, leveraging his extensive knowledge to make a profound impact on patients’ lives.

Advisors

Jeffrey L. Cleland, Ph.D.

Jeffrey L. Cleland, Ph.D.

ADVISOR
Dr. Cleland serves as Chairman, President and CEO of Ashvattha Therapeutics. He has years of industry experience in research and development, including more than a decade at Genentech, Inc. His experience in startups includes major roles in obtaining more than $500 million in capital at stages from Series A through D and exit via IPO--and has managed directly all aspects of drug development and late-stage research. He held leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as in early work on Lucentis®, Avastin®, and Kadcyla®. He holds a BS in Chemical Engineering from the University of California, Davis and a PhD in Chemical Engineering from the Massachusetts Institute of Technology. Dr. Cleland has authored more than 100 articles and four books and holds several issued patents.
Eduardo N. Chini, M.D., Ph.D.

Eduardo N. Chini, M.D., Ph.D.

ADVISOR
Eduardo N. Chini, M.D., Ph.D. is a faculty member at the Mayo Clinic. The research focus of Eduardo N. Chini, M.D., Ph.D., is in the fields of metabolism, nutrition, obesity, pharmacology, cancer and aging, and kidney disease. In particular, Dr. Chini is interested in nicotinamide adenine dinucleotide (NAD) metabolism and functions. He and his colleagues are exploring the nonoxidative and oxidative roles of NAD (as a signaling molecule and energy coin in cells). Dr. Chini's laboratory has done seminal work on NAD catabolism, including the description of the main enzyme responsible for the degradation of this molecule in mammalian tissues.

Partners & supporters

l4
l3
l2
l1
anni
URUGUAYLOGO

Eolo Pharma is a company dedicated to improving the health and well-being of individuals. Our high-quality products are designed to enhance energy and vitality, providing innovative solutions for healthcare.

Delaware, USA.

contact@eolo-pharma.com

Linkedin

Copyright © 2024 EoloPharma. All rights reserved.